Tuberous Sclerosis Complex

Overview

Tuberous sclerosis complex (TSC) is a lifelong genetic condition caused by disease-causing changes in either the TSC1 or TSC2 gene. These genes normally restrain a cell-growth pathway called mechanistic target of rapamycin (mTOR); when that restraint is lost, non-cancerous growths and developmental abnormalities can arise in the brain, kidneys, heart, skin, lungs, eyes, and other organs. TSC affects people of all sexes and ancestries, may be inherited or occur from a new genetic change, and varies widely even within the same family. 2021 International TSC Consensus recommendations

Prognosis ranges from relatively mild disease with independent adult life to medically complex disease involving epilepsy, developmental or behavioral differences, kidney disease, lung disease, or growing brain tumors. Current care is therefore lifelong and multidisciplinary: regular brain and kidney imaging, seizure monitoring and treatment, developmental and mental-health support, surgery or embolization when needed, and mTOR inhibitors such as everolimus or sirolimus for selected tumors, kidney angiomyolipomas, skin lesions, lung disease, and treatment-resistant seizures. These treatments can control manifestations but do not correct the underlying genetic cause. 2021 International TSC Consensus recommendations Rapamycin and rapalogs for TSC

Scope of Recent Research (2020–present)

Research activity has been substantial, with parallel efforts to prevent epilepsy before it becomes established, improve mTOR-pathway treatment, find mTOR-independent drug targets, and directly replace missing TSC1 or TSC2 gene function. The field is moving from symptom control toward biologically targeted intervention, but the most cure-oriented strategy—gene replacement—remains preclinical, with encouraging mouse evidence rather than human efficacy data. Gene therapy for TSC2 in mice AAV hamartin gene therapy for TSC1

Major Breakthroughs and Emerging Therapies

mTOR-pathway suppression remains the established disease-modifying foundation. Everolimus and sirolimus reduce the size of important TSC-associated lesions and can reduce seizure burden in some people, validating mTOR as a central therapeutic target. However, the benefit is generally suppressive rather than permanent: lesions may regrow when treatment stops, and treatment can cause adverse effects such as mouth ulcers, infections, and metabolic complications. Rapamycin and rapalogs for TSC MRI monitoring of everolimus response in a TSC mouse model

Gene replacement is the clearest potential route to a durable correction. In a 2021 mouse study of TSC2 deficiency, investigators packaged a shortened but functional “condensed” tuberin protein sequence into adeno-associated virus 9 (AAV9), a commonly used gene-delivery vector. A single intravenous dose substantially extended average survival from 58 to 462 days and reduced brain pathology in that model. Gene therapy for TSC2 in mice A 2025 study similarly found that systemic AAV9 delivery of human hamartin, the TSC1 protein, improved brain abnormalities and extended survival in a TSC1-deficient mouse model. AAV hamartin gene therapy for TSC1 These results are important proof-of-concept findings, but neither approach has yet established safety, dose, organ coverage, or effectiveness in people.

Researchers are also looking beyond mTOR for vulnerabilities that may persist despite mTOR inhibition. In TSC2-deficient cell models, inhibiting the redox-regulatory protein Ref-1 with APX3330 reduced signaling linked to inflammation, hypoxia, invasion, and abnormal blood-vessel-like behavior that mTOR inhibitors did not fully suppress. Ref-1 inhibition in TSC2-deficient cells Separately, patient-derived brain-lesion cells showed high epidermal growth factor receptor (EGFR) signaling, and the EGFR inhibitor afatinib reduced proliferation and viability in primary subependymal giant cell astrocytoma and cortical-tuber cells. EGFR targeting in TSC These are early laboratory findings, not established clinical treatments.

Epilepsy prevention is another attempt to alter the course of disease early in life. The EPISTOP study found that starting vigabatrin after epileptiform changes appeared on electroencephalography (EEG), but before clinical seizures, delayed seizures and was associated with lower rates of infantile spasms and drug-resistant epilepsy at 24 months. EPISTOP preventive-vigabatrin trial However, the randomized PREVeNT trial did not find improved cognition, fewer focal seizures, or less drug-resistant epilepsy at 24 months, although infantile spasms occurred later and less often in the early-treatment group. PREVeNT trial Together, these studies support intensive early EEG surveillance while showing that a true prevention strategy still needs refinement.

Clinical Trials and Experimental Approaches

Clinical development remains concentrated on seizure control rather than genetic cure. Marinus Pharmaceuticals completed the 129-participant global Phase 3 TrustTSC trial of adjunctive ganaxolone for TSC-related epilepsy in October 2024; the ClinicalTrials.gov record lists the study as completed, but no outcome results are posted in the registry record. TrustTSC Phase 3 trial A separate Phase 3 placebo-controlled study of full-spectrum cannabis extract for refractory TSC-related epilepsy began in June 2024 and planned enrollment of 84 participants, with completion estimated for June 2027. YCJ-01 cannabis-extract Phase 3 trial

Cannabidiol has more mature evidence as add-on seizure treatment, though it is not curative. In a 2024 report from a U.S. expanded-access program, 34 people with TSC and treatment-resistant epilepsy had median reductions in convulsive, focal, and total seizures across three years of follow-up, while somnolence, diarrhea, and ataxia were among the most frequent treatment-related adverse events. Three-year cannabidiol outcomes

Recent completed trials have also clarified limits of mTOR inhibition for neurocognition. The 2026 TRON randomized trial found that apparent neuropsychological “response” was common in both everolimus and placebo groups, making it difficult to demonstrate a reliable cognitive benefit; adverse events were reported more often with everolimus. TRON everolimus neuropsychology trial

Methodologies and Scientific Approaches

TSC researchers combine animal models with human, patient-derived models. AAV-based mouse models allow investigators to test whether gene replacement can restore hamartin or tuberin activity in the brain, while induced pluripotent stem cell-derived cortical organoids—three-dimensional laboratory models of early brain development—allow study of human TSC2 variants over time. Longitudinal multi-omics studies measure changes across RNA, proteins, and other molecular layers to identify disrupted developmental pathways and candidate drug targets. AAV hamartin gene therapy for TSC1 Longitudinal multi-omics cortical-organoid study

Kidney organoids, CRISPR-engineered cell lines, single-cell RNA sequencing, high-resolution magnetic resonance imaging, and serial EEG are also increasingly important. Renal organoid work has shown that loss of TSC1 or TSC2 can disrupt several developmental cell populations and can produce changes that are not fully corrected by rapamycin, helping explain why combination or replacement strategies may be necessary. Renal organoid modeling of TSC EEG biomarkers are being used to identify infants at high risk of severe epilepsy before seizures become clinically visible. EPISTOP preventive-vigabatrin trial

Leading Institutions and Funding

Major gene-replacement work has come from Massachusetts General Hospital–affiliated investigators, whose teams developed AAV9 approaches for both condensed tuberin replacement in TSC2 models and hamartin replacement in TSC1 models. Gene therapy for TSC2 in mice AAV hamartin gene therapy for TSC1 Other active academic groups include Emory University and Children’s Healthcare of Atlanta in cortical-organoid and multi-omics research, and the University of Ottawa and Ottawa Hospital Research Institute in kidney-organoid modeling. Longitudinal multi-omics cortical-organoid study Renal organoid modeling of TSC

The TSC Alliance is a central patient-led research funder and infrastructure partner. Its current and recent awards include projects on gene-therapy rescue of epilepsy, cortical organoids, somatic mosaicism, biomarkers, and variant interpretation. TSC Alliance grants and funding The U.S. Department of Defense Tuberous Sclerosis Complex Research Program reported an FY2024 appropriation of $8 million, award mechanisms up to $1.15 million, and approximately $121 million appropriated for TSC research since 2002; the TSC Alliance reported more than $37 million in research funding since 1984. TSC Research Program congressional packet

Strengths, Limitations, and Challenges

The major strength of TSC research is that the core biology is unusually well defined: loss of hamartin or tuberin causes excessive mTOR signaling, and mTOR inhibitors already provide clinically meaningful benefits for several manifestations. Gene replacement now offers a scientifically plausible way to restore missing function rather than continually suppressing downstream effects. Rapamycin and rapalogs for TSC Gene therapy for TSC2 in mice The recent TSC1 and TSC2 AAV studies also suggest that pathology can be improved after disease processes have begun in mouse brains. AAV hamartin gene therapy for TSC1

The obstacles are formidable. TSC2 is too large for standard AAV packaging in its full form, requiring engineered shortened versions whose long-term safety and completeness of function must be proven. Gene therapy for TSC2 in mice A future therapy would need to reach the appropriate cells across multiple organs, avoid problematic immune responses, remain durable, and be accessible despite the cost and complexity of gene therapy. In addition, early epilepsy-prevention trials have produced partly conflicting results, and mTOR inhibitors have not reliably improved cognition or broad neuropsychiatric outcomes. EPISTOP preventive-vigabatrin trial PREVeNT trial TRON everolimus neuropsychology trial

Outlook and Future Directions

As of September 30, 2026, TSC is not close to a clinically available cure, but it has stronger cure-oriented preclinical evidence than many multisystem genetic disorders because both disease genes and their major downstream pathway are known. The milestones to watch are replication of AAV-based TSC1 and TSC2 replacement in additional models, demonstration of safe whole-body and brain delivery, durable effects on seizures and organ lesions, development of biomarkers that identify who should be treated earliest, and eventual first-in-human gene-replacement studies. Until then, the most realistic near-term progress will be earlier diagnosis, better seizure prevention, safer combination treatments, and more individualized use of existing mTOR-directed therapies. AAV hamartin gene therapy for TSC1 TSC Research Program congressional packet

References

• 2021 International TSC Consensus recommendations — Northrup et al., 2021.
• Rapamycin and rapalogs for TSC — Samuel et al., Cochrane Database of Systematic Reviews, 2023.
• Gene therapy for TSC2 in mice — Prabhakar et al., Science Advances, 2021.
• AAV hamartin gene therapy for TSC1 — Abou Haidar et al., Molecular Therapy: Methods & Clinical Development, 2025.
• MRI monitoring of everolimus response in a TSC mouse model — McGill et al., Frontiers in Oncology, 2022.
• Ref-1 inhibition in TSC2-deficient cells — Dunlop et al., Cancers, 2022.
• EGFR targeting in TSC — Schachenhofer et al., Neuropathology and Applied Neurobiology, 2024.
• EPISTOP preventive-vigabatrin trial — Kotulska et al., Annals of Neurology, 2021.
• PREVeNT trial — Bebin et al., Annals of Neurology, 2023.
• TrustTSC Phase 3 trial — Marinus Pharmaceuticals and ClinicalTrials.gov, 2025.
• YCJ-01 cannabis-extract Phase 3 trial — ClinicalTrials.gov, 2025.
• Three-year cannabidiol outcomes — Weinstock et al., Epilepsia Open, 2024.
• TRON everolimus neuropsychology trial — Saxena et al., Journal of Medical Genetics, 2026.
• Longitudinal multi-omics cortical-organoid study — Zhang et al., 2024.
• Renal organoid modeling of TSC — Pietrobon et al., Cell Reports, 2022.
• TSC Alliance grants and funding — TSC Alliance, 2025.
• TSC Research Program congressional packet — TSC Alliance and U.S. Department of Defense Tuberous Sclerosis Complex Research Program, 2025.